Ft011 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 51 | 全身性強皮症 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04647890 (ClinicalTrials.gov) | February 2021 | 16/11/2020 | Effects of FT011 in Systemic Sclerosis | A Phase II, Randomised, Double Blind, Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamic Effects, and Safety, of Oral FT011 in Participants With Diffuse Systemic Sclerosis | Scleroderma, Systemic;Scleroderma, Diffuse;Sclerosis, Systemic | Drug: FT011;Drug: Placebo | Certa Therapeutics | NULL | Not yet recruiting | 18 Years | 75 Years | All | 30 | Phase 2 | NULL |